ZA200401103B - Process for the preparation of amorphous form of torsemide - Google Patents
Process for the preparation of amorphous form of torsemide Download PDFInfo
- Publication number
- ZA200401103B ZA200401103B ZA200401103A ZA200401103A ZA200401103B ZA 200401103 B ZA200401103 B ZA 200401103B ZA 200401103 A ZA200401103 A ZA 200401103A ZA 200401103 A ZA200401103 A ZA 200401103A ZA 200401103 B ZA200401103 B ZA 200401103B
- Authority
- ZA
- South Africa
- Prior art keywords
- torsemide
- preparation
- amorphous
- solution
- suitable solvent
- Prior art date
Links
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 title claims description 24
- 229960005461 torasemide Drugs 0.000 title claims description 24
- 238000000034 method Methods 0.000 title claims description 16
- 238000002360 preparation method Methods 0.000 title claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 150000002576 ketones Chemical class 0.000 claims description 3
- 150000002825 nitriles Chemical class 0.000 claims description 3
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 claims description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- PTTPXKJBFFKCEK-UHFFFAOYSA-N 2-Methyl-4-heptanone Chemical class CC(C)CC(=O)CC(C)C PTTPXKJBFFKCEK-UHFFFAOYSA-N 0.000 claims 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 1
- 229940043232 butyl acetate Drugs 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 150000004292 cyclic ethers Chemical class 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 239000002171 loop diuretic Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000000210 loop of henle Anatomy 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN830DE2001 IN192178B (xx) | 2001-08-03 | 2001-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200401103B true ZA200401103B (en) | 2006-04-26 |
Family
ID=11097098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200401103A ZA200401103B (en) | 2001-08-03 | 2004-02-11 | Process for the preparation of amorphous form of torsemide |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7002018B2 (xx) |
| EP (1) | EP1417172A4 (xx) |
| JP (1) | JP2005519862A (xx) |
| EA (1) | EA200400263A1 (xx) |
| IN (1) | IN192178B (xx) |
| NO (1) | NO20040485L (xx) |
| PL (1) | PL373892A1 (xx) |
| WO (1) | WO2003014086A1 (xx) |
| ZA (1) | ZA200401103B (xx) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7980900B2 (en) * | 2004-05-14 | 2011-07-19 | Commscope, Inc. Of North Carolina | Next high frequency improvement by using frequency dependent effective capacitance |
| WO2013132511A1 (en) * | 2012-03-09 | 2013-09-12 | Hetero Research Foundation | Novel polymorph of lurasidone hydrochloride |
| CN103694165B (zh) * | 2013-11-12 | 2016-05-04 | 江苏正大清江制药有限公司 | 吉美嘧啶无定形固化物及制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US30633A (en) * | 1860-11-13 | Improvement in fire-escapes | ||
| US34580A (en) * | 1862-03-04 | Improvement in brick-machines | ||
| GB1477664A (en) | 1974-04-17 | 1977-06-22 | Christiaens Sa A | Pyridine derivatives |
| DE3529529A1 (de) * | 1985-08-17 | 1987-02-19 | Boehringer Mannheim Gmbh | Verfahren zur herstellung einer stabilen modifikation von torasemid |
| HRP980532B1 (en) | 1998-10-02 | 2005-06-30 | Pliva | Novel crystalline torasemide modification |
| US6166045A (en) * | 1998-06-02 | 2000-12-26 | Roche Diagnostics Gmbh | Torasemide of modification III |
| US5914336A (en) | 1998-06-02 | 1999-06-22 | Boehringer Mannheim Gmbh | Method of controlling the serum solubility of orally administered torasemide and composition relating thereto |
| MXPA02001369A (es) | 1999-08-11 | 2005-08-26 | Teva Pharma | Torasemidas polimorfas. |
| HRP20000162B1 (en) | 2000-03-20 | 2004-06-30 | Pliva D D | Amorphous torasemide modification |
| HRP20000328A2 (en) | 2000-05-19 | 2002-02-28 | Pliva Farmaceutska Ind Dionik | Novel polymorph v of torasemide |
-
2001
- 2001-08-03 IN IN830DE2001 patent/IN192178B/en unknown
-
2002
- 2002-08-02 WO PCT/IB2002/003013 patent/WO2003014086A1/en not_active Application Discontinuation
- 2002-08-02 EA EA200400263A patent/EA200400263A1/ru unknown
- 2002-08-02 PL PL02373892A patent/PL373892A1/xx not_active Application Discontinuation
- 2002-08-02 US US10/485,590 patent/US7002018B2/en not_active Expired - Fee Related
- 2002-08-02 EP EP02755413A patent/EP1417172A4/en not_active Withdrawn
- 2002-08-02 JP JP2003519036A patent/JP2005519862A/ja not_active Withdrawn
-
2004
- 2004-02-03 NO NO20040485A patent/NO20040485L/no not_active Application Discontinuation
- 2004-02-11 ZA ZA200401103A patent/ZA200401103B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US7002018B2 (en) | 2006-02-21 |
| WO2003014086A1 (en) | 2003-02-20 |
| JP2005519862A (ja) | 2005-07-07 |
| EP1417172A1 (en) | 2004-05-12 |
| EA200400263A1 (ru) | 2005-06-30 |
| IN192178B (xx) | 2004-03-06 |
| EP1417172A4 (en) | 2005-05-11 |
| PL373892A1 (en) | 2005-09-19 |
| NO20040485L (no) | 2004-04-02 |
| US20040254223A1 (en) | 2004-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200401103B (en) | Process for the preparation of amorphous form of torsemide | |
| SK102294A3 (en) | Process for preparing of fibrinogen receptor antagonists matters | |
| CN112778219A (zh) | 一种制备 2,4-（1h, 3h）-喹唑啉二酮类化合物的方法 | |
| US7728173B2 (en) | Processes for preparing venlafaxine and venlafaxine hydrochloride of form I | |
| CA2694939C (en) | Process for producing toluidine compound | |
| CN112830896B (zh) | 西咪替丁的制备方法 | |
| AU728090B2 (en) | Intermediates for the preparation of 2-imidazoline-5-ones | |
| CN116583184A (zh) | 制备n-(1-甲基-1h-四唑-5-基)-2-(((2-甲基-2h-四唑-5-基)甲氧基)甲基)-6-(三氟甲基)烟酰胺的方法 | |
| Effenberger et al. | Amino acids; 13: Investigations on the synthesis of DL-serine from α-haloacrylic acid derivatives | |
| KR20160064139A (ko) | 소듐 하이오데옥시콜레이트 (NaHDC)의 다형 형태 및 그의 제조 방법 | |
| CN112939893A (zh) | 一种4-（4-氨基苯基）-3-吗啉酮的合成方法 | |
| CN108586369B (zh) | 苯基三嗪化合物的制备方法及苯基吡啶化合物的制备方法 | |
| CA3036936A1 (en) | Optimized production method for a 2-acyliminopyridine pest control agent | |
| CN111848423B (zh) | 3-氧代环丁基氨基甲酸叔丁酯的制备方法 | |
| AU780751B2 (en) | Process to prepare androst-4-en-17-carboxylic acid cross-reference to related applications | |
| CS226741B2 (en) | Method of preparing 5-alkyl-2-pyrazinecarboxylic acid | |
| CN116217391A (zh) | 一种氟代乙酸酯的合成方法 | |
| WO2024009206A1 (en) | A process for the preparation of edoxaban and its intermediates | |
| JPS63170353A (ja) | アミノチオアセトアミド類の合成法 | |
| KR100666191B1 (ko) | 4시아노페닐 이소시아네이트의 제조방법 | |
| CN115536599A (zh) | 法匹拉韦中间体3,6-二氟-2-吡嗪甲腈的制备方法 | |
| CN117623882A (zh) | 一种简便高效的柱[6]芳烃合成制备方法 | |
| CN114890902A (zh) | 2-甲基-3-三氟甲基苯胺的制备方法 | |
| CN115557903A (zh) | 一种特草定的制备方法 | |
| CN116354855A (zh) | 一种西维来司他钠的制备方法 |